Loading
Faeth Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by STEPHENSON BRIAN C, was filed 26 Jun 2026.
Insider Decl.
279
Thresholds
n/a
Buy Volume
€6M
113 ops. · all time
Sell Volume
€7M
40 ops. · all time
Who traded when
BuySaleMillennium Management LLC26 buys23 sales
Brian C. Stephenson16 buys
Cambrian BioPharma Inc7 sales
Peyer James4 sales
Anand Kiran Parikh1 buy
Since the insiders bought
- -9.3%Entry US$23.22 · Close 22 Oct 2026 US$21.07
- +27.9%Entry US$24.67 · Close at T+90 US$31.55
- +64.6%Entry US$19.91 · Close at T+90 US$32.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Faeth Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$56.14.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$20.79
Analyst consensus
14 analystsStrong buy
US$40.00Target US$56.14(+170%)US$70.00
Income statement
EBITDA-US$20.9M
Net income-US$21.1M0.0% margin
Valuation
PER (forward)-5.7x
P/Book3.1x
Beta-0.29
Balance sheet & cash
Market capUS$537.2M
Total debtUS$1.5M
Free Cash Flow-US$20.5M
Debt / Equity0%
Profitability & ownership
ROE-195.3%
ROA-20.8%
% insiders4.9%
% institutions80.9%
Last declaration on 11 August 2026
Declarations279 total
130,142 shares@ US$27.990.48% mcap100.0% of flowCommonSEC144:0001959173-26-005879
3,000 shares@ US$25.989.7% of flowCommon StockSEC:0001780030-26-000005:1
Canonical exit: 22 Sept 2026 (T+90)
3,400 shares@ US$26.9811.4% of flowCommon StockSEC:0001780030-26-000005:2
Canonical exit: 22 Sept 2026 (T+90)
100 shares@ US$26.390.3% of flowCommon StockSEC:0001780030-26-000005:7
Canonical exit: 24 Sept 2026 (T+90)
2,891 shares@ US$25.229.1% of flowCommon StockSEC:0001780030-26-000005:0
Canonical exit: 22 Sept 2026 (T+90)
1,358 shares@ US$25.554.3% of flowCommon StockSEC:0001780030-26-000005:6
Canonical exit: 24 Sept 2026 (T+90)
580 shares@ US$23.611.7% of flowCommon StockSEC:0001780030-26-000005:4
Canonical exit: 24 Sept 2026 (T+90)
100 shares@ US$27.770.3% of flowCommon StockSEC:0001780030-26-000005:3
Canonical exit: 22 Sept 2026 (T+90)
4,212 shares@ US$24.9013.0% of flowCommon StockSEC:0001780030-26-000005:5
Canonical exit: 24 Sept 2026 (T+90)
6,836 shares@ US$24.1220.4% of flowCommon StockSEC:0001780030-26-000004:5
Canonical exit: 21 Sept 2026 (T+90)
3,329 shares@ US$23.289.6% of flowCommon StockSEC:0001780030-26-000004:3
Canonical exit: 20 Sept 2026 (T+90)
356 shares@ US$23.951.1% of flowCommon StockSEC:0001780030-26-000004:4
Canonical exit: 20 Sept 2026 (T+90)
1,583 shares@ US$22.404.4% of flowCommon StockSEC:0001780030-26-000004:2
Canonical exit: 20 Sept 2026 (T+90)
425 shares@ US$25.911.4% of flowCommon StockSEC:0001780030-26-000004:7
Canonical exit: 21 Sept 2026 (T+90)
2,806 shares@ US$19.76100.0% of flowCommon StockSEC:0002111813-26-000010:0
Canonical exit: 20 Sept 2026 (T+90)
1,797 shares@ US$20.234.5% of flowCommon StockSEC:0001780030-26-000004:0
Canonical exit: 20 Sept 2026 (T+90)
1,969 shares@ US$24.846.1% of flowCommon StockSEC:0001780030-26-000004:6
Canonical exit: 21 Sept 2026 (T+90)
1,118 shares@ US$20.822.9% of flowCommon StockSEC:0001780030-26-000004:1
Canonical exit: 20 Sept 2026 (T+90)
45,252 sharesCommon StockSEC:0002111813-26-000010:1
8,213 sharesCommon StockSEC:0002111813-26-000010:2
476 shares@ US$21.140.054% mcap0.3% of flowCommon StockSEC:0000897069-26-001299:1
24,524 shares@ US$20.002.65% mcap12.2% of flowCommon StockSEC:0000897069-26-001299:0
3,099 shares@ US$30.86380.52% mcap4.8% of flowCommon StockSEC:0001104659-26-062608:3
2,992 shares@ US$25.07840.41% mcap3.8% of flowCommon StockSEC:0001104659-26-062603:11
Canonical exit: 28 Jun 2026 (T+90)
46 shares@ US$34.74640.0087% mcap0.1% of flowCommon StockSEC:0001104659-26-062605:16
25 of 279 declarations
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. has 204 filings, including 123 purchases worth EUR 6.9 million (median EUR 31,647) and 33 sales worth EUR 5.3 million (median EUR 27,202). This US healthcare company, listed on Nasdaq and valued at USD 537.2 million, is mostly traded by institutional holders: Cambrian BioPharma Inc, a 10% owner, signs 50 filings, 41 of them purchases; Millennium Management LLC signs 49, with 26 purchases and 23 sales.
The largest sale, EUR 3,650,066, is Apeiron Investment Group Ltd.'s on June 1, 2023. The largest purchase, EUR 303,691, comes from Cambrian BioPharma Inc on December 29, 2021; James Peyer, a director, and Cambrian each bought EUR 250,823 on February 24, 2021. Between December 9, 2021 and December 30, 2021, 3 filers bought for EUR 701,471. Across the full history, 89 purchase filings are classed as clustered.
Read moreShow less
Annual volume goes from 65 filings in 2021 to 3 in 2024, then to 71 in 2026. The last twelve months hold 74. For 70 purchases with a 90-day result, the median is 24.2%, with 61% of results positive (recorded past results, not a forecast).
